Late-onset severe pneumonitis under osimertinib

Zulfiya Syunyaeva; Katharina Berghof; Diego Kauffmann-Guerrero; Jeremias Götschke; Amanda Tufman; Kathrin Kahnert

doi:10.21037/acr.2019.09.01

Late-onset severe pneumonitis under osimertinib

AME Case Rep. 2019 Oct 15:3:39. doi: 10.21037/acr.2019.09.01. eCollection 2019.

Authors

Zulfiya Syunyaeva^{1

2}, Katharina Berghof^{1

2}, Diego Kauffmann-Guerrero^{1

2}, Jeremias Götschke^{1

2}, Amanda Tufman^{1

2}, Kathrin Kahnert^{1

2}

Affiliations

¹ Division of Respiratory Medicine and Thoracic Oncology, Department of Internal Medicine V, University of Munich (LMU), Thoracic Oncology Centre Munich, Munich, Germany.
² Comprehensive Pneumology Center, Member of the German Center for Lung Research (DZL), Munich, Germany.

Abstract

Pneumonitis is a rare and possibly life threatening side effect of TKI-treatment. We present a patient with adenocarcinoma of the lung harboring an uncommon EGFR Exon 21 mutation treated with osimertinib as second-line therapy. After nine months of treatment, the patient developed progressing shortness of breath and night sweats. A severe late-onset predominantly eosinophilic pneumonitis was diagnosed, osimertinib treatment was discontinued and immunosuppressive treatment was initiated. This case report highlights late-onset pneumonitis as a side effect of third-generation TKI-treatment and possible options for subsequent tumor treatment.

Keywords: Pneumonitis; interstitial lung disease; late onset; non-small cell lung cancer (NSCLC).

Publication types

Case Reports